Equity Research Analysis: MEDICINOVA INC (MNOV)
|Blank Capital Research Unit|Spot: $1.36
Price$1.36
Composite Score42.4/100
RatingREDUCE (2★)
Rank#3200 OF 7,333
Market Cap$62M
ROE
Intelligence Feed
MarketBeat4d ago Negative
MediciNova (NASDAQ:MNOV) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS
MediciNova (NASDAQ:MNOV) reported quarterly earnings of ($0.05) EPS, surpassing analyst estimates by $0.05, with revenue of $0.15 million. The biopharmaceutical company's shares traded down 0.7% to $1.54, giving it a market capitalization of $75.64 million. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $7.00.
www.streetwisereports.comFeb 2 Positive
Drug Developer Uncovers Excellent Progress in 200-Patient ALS Study
MediciNova Inc. (MNOV:NASDAQ) announced significant progress in its SEANOBI study for ALS, with 100 patients enrolled across 12 sites in the U.S., reaching 50% of its target. The study, funded by a US$22 million NINDS grant, evaluates ibudilast (MN 166) in ALS patients not eligible for randomized trials, aiming to gather critical real-world biomarker and clinical outcome data. This expanded access program complements the ongoing COMBAT ALS Phase 2b/3 trial, with both studies providing evidence to support future regulatory discussions for ibudilast as an ALS treatment.
Stock TitanJan 29 Positive
ALS patients gain wider access as MediciNova trial reaches 100 enrollees
MediciNova (NASDAQ:MNOV) announced that 100 patients have been enrolled in the NIH-funded SEANOBI Expanded-Access Program (EAP) evaluating MN-166 (ibudilast) for ALS, reaching 50% of its 200-patient goal across 12 US sites. This program, backed by a $22 million NINDS grant, provides real-world biomarker and clinical outcome data, complementing the ongoing COMBAT-ALS Phase 2b/3 randomized trial, which is fully enrolled with 234 patients and expects topline results by the end of 2026. The SEANOBI EAP aims to offer MN-166 access to ALS patients who are not eligible for randomized trials.
MarketBeatJan 7 Negative
MediciNova (NASDAQ:MNOV) Rating Increased to Strong-Buy at Lucid Cap Mkts
Lucid Cap Mkts has upgraded MediciNova (NASDAQ:MNOV) to a "strong-buy" rating. Despite mixed analyst opinions, the stock holds a consensus "Moderate Buy" rating with an average price target of $7.00. MediciNova is a clinical-stage biopharmaceutical company focusing on small-molecule therapeutics, with its lead asset MN-166 (ibudilast) being a key focus.
Investing.comJan 1 Negative
MediciNova enters $50 million equity distribution agreement with Lucid Capital
MediciNova (NASDAQ:MNOV) has announced an equity distribution agreement with Lucid Capital Markets, allowing them to sell up to $50 million of common stock through at-the-market offerings. This move is necessitated by the biotechnology company's significant cash burn, with a negative free cash flow of $9.73 million over the past year. The agreement provides financial flexibility as MediciNova continues to advance its clinical trials for MN-166 in conditions like chemotherapy-induced peripheral neuropathy and amyotrophic lateral sclerosis.